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http://dx.doi.org/10.1016/j.kjms.201Abstract Hepatocyte growth factor (HGF), a potent cytokine of mesenchymal origin, exhibits
polytrophic physiological responses, including proliferation, migration, and invasion, in a wide
variety of cells. Although it is known that inhibition of the responses by HGF variants was via
signal transducers and activators of the transcription pathway, the mechanisms of action of
the variants involved in the production of matrix metalloproteinases (MMPs) were not clearly un-
derstood. Thus, recombinant HGF variants, NK1, NK2, NK3, and NK4 were topically applied to as-
says for proliferation, migration, invasion, and expression of MMPs in the human lung cancer cell
line A549 and compared to that of control medium and a glutathione-s-transferase control. Re-
sults showed that these recombinant HGF variants significantly inhibited proliferation, migra-
tion, and invasion of A549 at >4 nM, downregulated expression of MMP-9, and upregulated
expression of MMP-8. The study clearly suggests that binding of the HGF variants to the cell sur-
face c-Met resulted in the downregulation of MMP-9, and upregulation of MMP-8 protein expres-
sions might be key molecular signals against proliferation, migration, and invasion of A549 cells.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.t of Biological Sciences, Na-
hai Road, Kaohsiung 80424,
ysu.edu.tw (S. He).
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Hepatocyte growth factor/scatter factor (HGF) is a hetero-
dimeric protein consisting of two chains, a-chain (surface
molecular weight of 69 kDa) and b-chain (34 kDa) [1]. This
protein has been shown to exhibit pleiotropic functions, suched by Elsevier Taiwan LLC. All rights reserved.
MMP expression regulated by HGF variants 531as regeneration of liver tissue [2], mitogenesis of hepato-
cytes [3], morphogenesis of embryogenic tissue [4], and
angiogenesis in a variety of epithelial and endothelial cells
[5]. Tumor cells are highly proliferative, invasive, and met-
astatic in nature, and so when tumor and host cells interact,
many remodeling dynamics occur by degradation of the
extracellular matrix (ECM) and motogenic responses are
acquired [6]. The above processes do not occur if HGF does
not interact with its high affinity receptor c-Met, a tyrosine
kinase and proto-oncogene [7]. Although the majority of
mutations leading to amino acid alterations in the receptor
decrease protein functions, many missense mutations
in some cancer cells increase tyrosine kinase activity [8];
hence the interaction sites between HGF and c-Met are an
interesting target for competitive inhibition of c-Met
phosphorylation.
The N-terminal of the HGF a-chain includes four kringle
domains: NK1 (amino acids 32e122), NK2 (128e206), NK3
(211e288), and NK4 (305e383) [9]. These domains are
independently folded, and involved in proteineprotein in-
teractions and regulating certain biological functions [10].
The kringle4 domains of the HGF a-chain could compete in
binding to c-Met; for example, NK1 (a product of HGF
degraded by factor Xa) exhibits antagonist activity on
mitogenic and motogenic actions of HGF [11e13], and
engineered recombinant NK1, NK2, NK3, and NK4 exhibited
antagonists to mitogenic and motogenic activities of HGF in
human breast cancer cells (MDA-MB-435s), derived from
endothelial cells [14]. Thus, independent binding of four
intermolecular fragments, NK1, NK2, NK3, and NK4 to c-Met
exhibited agonists and antagonists to HGF. Other studies of
fragment NK4, which lacks agonistic activity, have shown
that it inhibits the receptor’s dimerization and future
signaling from the c-Met receptor in the cytoplasmic space
as a competitive antagonist, and it then abrogates the
biological activities of HGF [15,16].
Increased degradation of the ECM by matrix metal-
loproteinases (MMPs) plays a major role in tumor growth and
metastasis in the participation of various physiological
functions, such as the remodeling processes, embryogenesis,
invasion, and angiogenesis [17e19]. Twenty MMPs have
been divided into six groups based on similarities in struc-
tures and substrate-specific activities. Functions of MMP
suchas gelatinases [MMP-2 (gel-A) andMMP-9 (gel-B)] include
degradation of major components of the ECM and basement
membrane proteins. MMP-2 is activated mainly by cell sur-
face membrane-bound metalloproteinase (MT-MMP-1,-2,-3)
and blocked by tissue inhibitory metalloproteinase-2 [20].
However, MMP-9 is not activated by MT-MMP1 but rather by
MMP-3 [21], MMP-2 [20], and plasmin [22]. The enhanced
expression of both gelatinases (MMP-2 and MMP-9) has been
reported in colon [23], breast [24], and bladder [21] cancers,
but in some other tumors, this pair do not coexist.
Apart from gelatinases, collagenases also take part in
the degradation of fibrin and noncollagen substances, and
include collagenase-1 (MMP-1), collagenase-2 (MMP-8), and
collagenase-3 (MMP-13), which are found to play a role in
wound repair in the alveolar epithelium by decreasing cell
adhesion and cell stiffness [25,26]. The involvement of
collagenases in the metastasis has been observed in many
tumors, but little was known about their diagnosis and
prognosis. MMP-1 and MMP-13 have been shown to promotemigration by reducing cell adhesion [25], but there is also a
report regarding secretion of MMP-8 by the human non-
small-cell lung carcinoma A549 cell line being stimulated
by cytokines such as tumor necrosis factor-a [27]. MMP-8
belongs to the collagenase group of the MMP family, a
product of neutrophils, which are identified as antitargets
for therapy of cancers and expressed in various cell types,
such as plasma cells [28], macrophages [29], endothelial
cells [30], fibroblasts [31], and keratinocytes [32]. The
protective role of MMP-8 has come from a classical exper-
iment using carcinogens for skin tumors in mice [33]. Non-
metastatic M-4A4 cells secrete 20% more MMP-8 than
metastatic NM-2C5 [34]. In vivo evidence came from in-
jection of melanoma B16F10 containing MMP-8 into the tail
vein of C57BL/6 mice, which caused an almost 70% reduc-
tion of metastasis when compared with the control B16F10
cells [26]. The report also suggested that exogenous
application of recombinant MMP-8 reduced the invasive
potential by approximately 80%. The same phenomenal
activity was observed on tongue squamous cell carcinoma,
breast cancer [35,36], and lymph node metastasis [35e37].
Previous studies showed that the interaction between
HGF and c-Met resulted in secretion of MMPs, but A549 cells
do not seem to express and secrete HGF. The receptor
tyrosine kinase phosphorylation was reported via the STAT3
pathway activated by Src-kinase [38,39]. Molecular mech-
anisms of functional inhibition or promotion of MMP-2,
MMP-8, and MMP-9 stimulated by HGF variants, however,
have not been studied to date. Therefore, the current
study focuses on the investigation of the mechanism of
actions of recombinant HGF variants purified as fusion
proteins with glutathione-s-transferase (GST) as their tags
and assayed on cell proliferation, migration, and invasion of
A549 cells. Our present work with HGF variants revealed
that upregulation of MMP-8 and downregulation of MMP-9
were key mechanisms for the cellular inhibition of human
carcinoma A549.
Methods
Reagents
Reagents used included acryl-amide (MD Bio, Taipei,
Taiwan), L-15 media (Gibco, Carlsbad, CA, USA), fetal
bovine serum (Biological Industries, Kibbutz Belt Haemek,
Israel), crystal violet (SHOWA, Tokyo, Japan), isopropyl b-D-
1-thiogalactopyranoside (IPTG; MD Bio, Taipei, Taiwan),
prestained sodium dodecyl sulphate (SDS)-polyacrylamide
gel (PAG) electrophoresis standards (Bio-Rad, Hercules, CA,
USA), 10X trypsin-EDTA (Biological Industries), goat anti-
human HGF, rabbit antigoat immunoglobulin conjugated
with horseradish peroxidase (HRP), goat antihuman GST,
rabbit antigoat conjugated with HRP (Santa Cruz, CA, USA),
enhanced chemiluminescence reagent (Perkin Elmer, Wal-
tham, MA, USA). General chemicals were obtained from
Sigma (Steinheim, Germany).
Plasmid clones and bacterial strains
DNA fragments for HGF variants (NK-1, NK-2, NK-3, and NK-
4) were amplified by PCR, cloned in a TA cloning vector
532 R. Ramanujum et al.(Promega, Madison, WI, USA), sequenced, and then cloned
into PGEX-2T. The bacterial strains BL21 (DE3; Takara Bio
Inc, Shiga, Japan) were used for expression where the
plasmids were transformed and grown in LB media (1 g
tryptone, 0.5 g yeast extract, 1 g sodium chloride, 100 mL
of distilled water, pH 7.2) containing 100 mg/mL ampicillin.
Expression and purification of recombinant HGF
variant proteins
Expression and purification of recombinant HGF variant
proteins were carried out similarly as previously reported
[40,41] with modifications. Briefly, the clones in pGEX-2T
(pGEX-2T/NK-1, pGEX-2T/NK-2, pGEX-2T/NK-3, and pGEX-
2T/NK-4; AmershamePharmacia, Uppsala, Sweden) were
transformed into BL21 (DE3) and grown to a log phase of 0.6
OD600 in LB media containing 100 mg/L ampicillin at 37
C.
Protein expression was induced by the incorporation of
1mM IPTG at 22C, and continued to culture for 6 hours.
Cells collected by centrifugation at 5000g for 20 minutes at
4C were lysed by sonication in the extraction buffer
(10 mg/L aprotinin, 1mM phenylmethylsulfonylfluoride,
10 mM benzimidine, 1% Triton X-100, 95% glycerol, 2 g/L
lysozyme) for five cycles, lasting 9 seconds, with a resting
interval of 20 seconds on ice. The clear supernatant ob-
tained from centrifugation at 12,000g for 30 minutes at 4C
was added to 100 mL of glutathione-sepharose beads
(AmershamePharmacia) in an ice cold binding buffer C
(20 mM Hepes, 100 mM KCl, 20% glycerol, 1 mM DTT, 1 mM
EDTA), kept in a rotating incubator for 4 hours at 4C. The
beads were collected, washed three times in binding
buffer, and then fusion proteins were eluted with binding
buffer containing 10 mM reduced glutathione. Reduced
glutathione was removed by dialysis, and purity was
checked in 12% SDS-PAG. The protein concentration was
calculated using the formula A280  1.55 e A260  0.75.
Detection of recombinant human HGF variants in
Escherichia coli
The experiment was carried out according to the method
reported in a previous study [42] with modifications.
Briefly, protein extracts separated on 12% SDS-PAG were
transferred to a nitrocellulose membrane (Millipore, Bed-
ford, MA, USA). The membrane was blocked in TBST (10 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20) containing
5% skimmed milk for 2 hours, washed with TBST buffer
three times, and incubated with primary antibody goat
anti-human HGF (1:2000; Sigma) overnight at 4C, and
subsequently incubated with the secondary antibody rabbit
antigoat IgG (1:5000) conjugated with HRP for 4 hours, by
washing the primary antibody with TBST. Detection of
bands was carried out by an enhanced chemiluminescent
reagent according to the manufacturer’s instructions, and
bands were analyzed by LAS3000 luminescent image
analyzer (FUJIFILM Co, Tokyo, Japan). For the identification
of GST protein, primary antibody goat anti-Schistosoma
japonicum GST (sjGST; 1:3000; Sigma) and secondary anti-
body rabbit antigoat Ig conjugated with HRP (1:5000) was
applied, and the band was visualized similarly to the re-
combinant HGF variant proteins as described above.Binding of sjGST to A549
The binding of sjGST with A549 was carried out in a model
of cell attachment: A549/GST/1st Ab/2nd
Ab/development. Briefly, 3  104 A549 cells were seeded
in 96-well plates (BD Biosciences, Taipei, Taiwan), and then
cultured overnight. The recombinant sjGST protein purified
from E. coli was added in a series of different concentra-
tions (1 nM, 5 nM, 100 nM, 1000 nM) and incubated at 37C
overnight. The culture media were discarded, and the cells
were washed with 1  phosphate buffered saline (PBS, pH
7.4) twice, incubated with primary antibody goat anti-GST
(1:3000) for 1 hour, washed twice with 1  PBS (pH 7.4),
and then incubated with secondary antibody, rabbit anti-
goat conjugated with HRP (1:5000) for another hour. The
plates were washed and the presence of HRP was identified
by the addition of diaminobenzidine (Sigma). Following
incubation for 10 minutes, the colored plates were read on
calibrated Model 5500 microplate reader (Bio-Rad) at
570 nm. A positive control was carried out using 3  104
MDA-MB-435s developed with the same procedure
described earlier.
Cell lines and culture
The A549 human lung adenocarcinoma cells obtained from
the American Type culture collection (ATCC CCL-185,
Manassas, VI, USA) were maintained in L-15 media con-
taining 10% fetal bovine serum, 50 g/L penicillin, and
100 mg/L streptomycin (Hyclone Laboratories, Inc., Logan,
UT, USA) at 37C in a humidified chamber with replacement
of the media every 2 days as described [43,44] with
modifications.
Proliferation assay
The entire process was carried out according to the pro-
tocol as reported [14,43], with some modifications in a
predetermined period of 8 days where approximately 1000
cells were incubated in the 96-well plates with L-15 media,
containing 10% fetal bovine serum at 37C in an incubation
chamber, with respect to HGF variant proteins (NK1, NK2,
NK3, and NK4), GST at 4 nM. At each interval of 2 days, fresh
media and proteins were added and plates were collected
at the end of 2 days, 4 days, 6 days, and 8 days. The ob-
tained plates were washed with 1  PBS (pH 7.4) twice,
fixed by 4% formaldehyde for 30 minutes, washed and
stained with 100 mL of 0.2% crystal violet for 20 minutes,
destained four times with water, air-dried, and photo-
graphed. The crystal violet dye was solubilized in 1% (w/v)
SDS (Sigma) by incubating at 37C for 1 hour, and quantified
by measuring the absorbance at 570 nm, using a calibrated
Model 5500 microplate reader (Bio-Rad). Three indepen-
dent repeats were carried out.
Migration assay
The in vitro scratch or wound healing assay was carried out
as reported [43,45] with modifications. Briefly, a uniform
cell-free area was created by scratching the confluent layer
of A549, with blue pipette tips in 24-well plates (BD
Figure 1. Western blotting of the Escherichia coli protein
isolates and sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) of purified hepatocyte growth
factor (HGF) variants. (A) SDS-PAGE of purified HGF variants
showing some degradation from NK3 and NK4. Protein bands
were labeled on the right of the gel. (B) Western blotting of
E. coli isolates. Protein bands were transferred from the SDS-
PAGE to a nitrocellulose membrane and recognized by the
goat antihuman HGF antibody followed by rabbit antigoat
immunoglobulin conjugated with horseradish peroxidase, and
developed with chemiluminescent reagent and visualized
through anLAS3000 luminescent image analyzer (Fujifilm).
Protein bands are labeled on the right of the gel.
MMP expression regulated by HGF variants 533Biosciences). The detached cells were washed with serum-
free L-15 media and incubated in media containing re-
combinant HGF variant proteins (NK1, NK2, NK3, and NK4),
or GST at 4 nM. Cell plates were collected at the end of
0 hours, 6 hours, 12 hours, 24 hours, 36 hours, and 48 hours,
washed twice with 1  PBS (pH 7.4), fixed by 4% formal-
dehyde for 30 minutes, washed again with water, and
stained with 0.2% crystal violet for 20 minutes, air dried,
and photographed. The closure of the wound, where the
number of cells migrated, was monitored under a 10
inverted microscope. The cells that migrated were counted
in a blinded fashion based on the camera records. Three
independent experiments were carried out.
In vitro Boyden chamber experiment
Invasion assays were carried out according to our previously
described procedures [14,43] by 24-well Boyden chamber,
100 mL of Matrigel (1 g/L; Collaborative Biomedical Prod-
ucts, Bedford, MA, USA) in ice-cold water, applied to 8-mm
pore size polycarbonate membrane filters (Becton Dick-
inson, Franklin Lakes, NJ, USA), incubated for 3e4 hours at
room temperature for gelling, briefly washed, and
6.25  105 cells were applied on the upper chamber, with
appropriate serum-free L-15 medium (50 mL). The lower
portion of the well was filled with 500 mL of L-15 medium
containing 10% FBS as a chemoattractant. Each of the re-
combinant HGF variants (NK1, NK2, NK3, NK4) or GST was
added at 4 nM. Plates were incubated for 36 hours at 37C.
The cells that had invaded the lower well were fixed with
4% formaldehyde, stained by crystal violet for 30 minutes,
washed with water, air dried, and counted under the 10
objective of a light microscope. Three independent tests
were carried out.
Quantitative zymography
To determine the production of MMPs (MMP-2 and MMP-9),
A549 cells were grown to sub-confluence (70%). The serum-
supplemented medium was removed, the cells were briefly
washed twice with 1  PBS (pH 7.4), and an MMP extraction
and quantitative zymographic experiment was carried out as
previously described [41,45] with modifications. Briefly, cells
were cultured in a serum-free L-15 (conditioned medium)
with recombinant HGF variants at 4 nM for 24 hours. Condi-
tioned media were removed, concentrated 10 times, mixed
with 2  sample buffer (1:1; 2.8 mL dH2O, 1 mL of 0.5 M Tris-
HCl pH6.8, 0.8mLglycerol, 3.2mL10%w/v SDS, and 0.2mLof
0.2% bromophenol blue). Supernatant proteins (20 mL) solu-
bilized in the sample buffer without boiling or addition of any
reducing agents, were separated in 8% SDS-PAGE containing
2% gelatin as a substrate. After electrophoresis, gels were
washed three times in 2.5% Triton X-100 with 20 minute
intervals, incubated in 50 mL of reaction buffer (2M Tris-HCl
pH 7.6, 1M CaCl2$2H2O) for 16e18 hours at 37
C. The gels
were washed with double distilled water and stained with
0.1% Coomassie brilliant blue for 1 hour, followed by
destaining until the appearance of white bands under the
blue background were visualized. The bands were quantified
by Image J software 1.32 (NIH, Bethesda, MD, USA) where
three independent experiments were performed. For caseinzymography, the entire protocol is similar to gelatine
zymography but gelatine is replaced with casein.
Statistical analysis
Statistical significance was carried out by two-way Student
t tests for proliferation, migration, invasion, and gelatine
zymography; p < 0.05 was considered significant, p < 0.01
very significant, and p < 0.005 as extremely significant.Results
HGF variants expressed in E. coli were detected by
Western blotting
DNA fragments for HGF variants NK1, NK2, NK3, and NK4
were cloned into pGEX-2T, linking the N-terminus of HGF
variants to the C-terminus of sjGST. The recombinant HGF
variants were synthesized in water-soluble form when the
temperature was reduced to 22C, after the addition of
IPTG. Protein bands separated by 12% SDS-PAG electro-
phoresis were transferred to a nitrocellulose membrane
(Millipore) and were recognized by the primary antibody
(goat anti-human HGF), followed by rabbit antigoat IgG
conjugated with HRP. The protein bands were identified by
an enhanced chemiluminescent reagent, where NK1 and
NK2 were seen as a single band, and NK3 and NK4 with
degradation (Fig. 1B) as previously reported [14]. Degra-
dation of recombinant NK3 and NK4 was also confirmed by
SDS-PAG electrophoresis stained with Coomassie blue
(Fig. 1A).
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Because both sjGST [41] and human GST [43] were shown to
bind with the human cancer cell line MDA-MB-435, an
experiment was set up to study which part of the GST-linked
HGF variants actually interact with the human lung cancer
cell line, A549. The cancer cells were incubated with sjGST
in a series of concentrations (1 nM, 5 nM, 100 nM, and
1000 nM) at room temperature for 1 hour, and washed three
times with PBS. Then, goat anti-sjGSTwas added, incubated,
washed, and developed. Results showed similar absorbance
at 570 nm to the two relevant controls, the medium and
secondary Ab. This suggests that sjGST does not bind to
A549, and any interaction between GST-HGF variants and
A549 comes from HGF variants, but not sjGST. By contrast,
sjGST binds well to MDA-MB-435s (Fig. 2).Figure 3. Proliferation assays for A549 in the presence of he-
patocyte growth factor (HGF) variants. Treatments of control and
glutathione-s-transferase (GST) are the medium only and the
addition of GST at 4 nM, respectively. Other treatments are A549
cells in thepresenceof recombinantHGFvariants,NK1,NK2,NK3,
and NK4 at the final concentration of 4 nM concentration, and the
living cellswere quantifiedby absorbanceat 570 nmafter staining
with crystal violet. All data were calculated from three inde-
pendent experiments (*p < 0.05, **p < 0.01).Recombinant HGF variants inhibit proliferation of
A549
To determine the effective role of recombinant HGF vari-
ants on the proliferation of A549, in vitro proliferation as-
says were performed for a pool of 8 days in the presence of
recombinant HGF variants. The results showed consistency
to previous histidine-tagged HGF variants on MDA-MB-435s
cells [14]. All the HGF variants inhibited the growth of
human lung adenocarcinoma A549 significantly. The results
are plotted in Fig. 3 and showed that the inhibition started
from Day 2. Statistical results showed that the inhibition
was significant (p < 0.05) in comparison with the medium
and GST controls. The inhibition continued to the end of theFigure 2. Assays for the binding of Schistosoma japonicum
glutathione-s-transferase (sjGST) to A549 and MDA-MB-435s.
Assays were carried out in medium only and with a second
antibody only as negative controls, sjGST at the final concen-
trations of 1 nM, 5 nM, 100 nM, and 1000 nM with A549 and
MDA-MB-435s cells. All data were calculated from three inde-
pendent experiments (***p < 0.005).proliferation experiment. In the Day 4 assay, for example,
the inhibition reached the p < 0.01 level between medium/
GST control and NK1. The trend of inhibition during the Day
6 and Day 8 assays was similar, with the growth difference
reaching a significant level (p < 0.05) between medium/
GST controls and HGF variants. By the end of 8 days, NK4
had shown the greatest inhibition followed by NK2 and NK1.
Recombinant HGF variants inhibit migration of
A549
To determine the significance of the influence of HGF var-
iants on the migration of human adenocarcinoma A549,
wound-healing assays were performed to record the
migrated cells in the wound area in the culture plate [43].
As described above, the stained plates collected were
visualized at 10 through a microscope and the effective-
ness of all recombinant HGF variants suppressed the
motility of human lung carcinoma A549 cells. The migrated
cells were counted and plotted in Fig. 4A, and showed that
cell migration was slowed down significantly in the pres-
ence of HGF variants (p < 0.05) even in a 6-hour incubation
compared with medium and GST controls. The pattern of
inhibition continued similarly in 12 hours, 24 hours, and 36
hours. By the end of 48 hours, the migration difference
reached p < 0.01 significance between medium/GST con-
trol and HGF variants (Fig. 4A).
HGF variants inhibit the invasion of A549
The invasion assay was performed with an 8-mm Boyden
chamber where the cells in the upper chamber invaded the
lower chamber by crossing the membrane according to a
previous description [14]. Only a few cells invaded the
Figure 4. Migration and invasion assays for A549 cells in the
presence of hepatocyte growth factor (HGF) variants. (A) The
number of cells migrating into the wound area. (B) The number
of cells invading the lower chamber in the presence of HGF
variants (NK1, NK2, NK3, and NK4) at the final concentration of
4 nM. Three independent experiments were carried out and
cells that migrated into the wound were counted under a mi-
croscope (*p < 0.05, **p < 0.01).
MMP expression regulated by HGF variants 535lower chamber in the first 24 hours, so the incubation time
was extended for another 12 hours. The cells in the lower
chamber were stained and counted manually using a 10
objective lens microscope (Fig. 4B). All the recombinant
HGF variants significantly (p < 0.05) inhibited the invasion
of A549 in comparison with GST and medium controls.
Three independent experiments were performed.
Regulatory expressions of MMP-8 and MMP-9 in
A549 in the presence of HGF variants
In order to study the mechanism of action of HGF variants
on the inhibition of proliferation, migration, and invasion in
A549, zymographic experiments were carried out, and
quantification of MMP expression was performed. The
conditioned media L-15 were subjected to zymographic
analysis to quantify MMP activities, based on substrate
specificity (gelatin and casein). Gelatinase activity was
visualized on zymographic gel (Fig. 5A) where there were
two clear bands at 72 kDa and 92 kDa. Gelatinase A (72 kDa,MMP-2) [45] and gelatinase B (92 kDa, MMP-9) [41] were
shown to be differentially expressed in the presence of HGF
variants. The density of bands was measured by Image J
software. The difference of MMP-2 and MMP-9 activities
generated by A549 cells in either medium or in the presence
of sjGST was not significant, suggesting that sjGST was not
involved in the stimulation of production of the MMPs.
Moreover, apart from NK4, which was shown to down-
regulate the expression of MMP2, the other variants (NK1,
NK2, NK3) were less effective in the generation of MMP2
(Fig. 5B). However, the activity of MMP-9 was significantly
downregulated in the presence of any of the four HGF
variants (Fig. 5A, p < 0.01e0.005). Variant NK4 was shown
to be the strongest inhibitor to the expression of MMP-9
(Fig. 5A). Casein zymographic assay was more sensitive
than the gelatin, where two bands at 92 kDa (MMP-9) and
75 kDa (MMP-8) were clearly detected (Fig. 5B). The
pattern of inhibition of MMP-9 was similar to the gelatin
zymographic assay but MMP-8 was significantly more highly
expressed in the presence of recombinant HGF variants.
The band intensity of MMP-8 stimulated NK4 is the highest
of all variants, suggesting a relationship between upregu-
lated expression of MMP-8 and the inhibition of prolifera-
tion, migration, and invasion of A549 cells.Discussion
Classical coupling of HGF and c-Met leads to the receptor’s
dimerization and tyrosine phosphorylation, directing
different cellular responses [1e5]. It is well documented
that many cancer cells highly express both HGF and c-Met
[30]. A previous study indicated that HGF variants bind
competitively to the HGF receptor c-Met, inhibiting or
slowing down the physiological functions conducted by HGF
[14]. The DNA fragment for each HGF variant was inde-
pendently cloned into the pGEX-2T expression vector,
expressed as a soluble-form recombinant protein in E. coli,
and identified by western blotting (Fig. 1). The difference
of proliferation assays between medium control and that in
the presence of GSTwas not statistically significant (Fig. 2).
This suggests that sjGST is not involved in proliferation,
migration, and invasion in A549 cells. This allowed us to
assay for inhibitory functions of HGF variants to A549 cells
in proliferation (Fig. 3), migration (Fig. 4A), and invasion
(Fig. 4B) directly with GST-tagged HGF variants, and thus
cleavage of GST-tagged HGF variants by thrombin was not
required. Assays for GST binding to A549 cells, with
different concentrations from 1 nM to 1000 nM of GST,
showed similar growth to the medium control, further
confirming that the influence of sjGST to A549 was not
significant at all (Fig. 2), but GST provides stability to re-
combinant HGF variants. Our data were similar with respect
to the exogenous application of GST on prostate cancer
cells (DU-145, P69), where the application of GST at 50 mg/
L showed equal growth towards the medium control [46].
However, recent work from our laboratory showed that
sjGST and human GST enhanced proliferation, migration,
and invasion of MDA-MB 435s cells and thus concluded that
there should be GST receptors at the surface of the human
cells, which were studied by fluorescent microscopy and
flow cytometry [41,43].
Figure 5. Gelatine/casein zymographic assays for the activities of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-8 in the
presence or absence of hepatocyte growth factor (HGF) variants. Zymographic gel of conditioned media supernatants, obtained
from A549 cells treated with recombinant HGF variants (4 nM). Lanes 1e6 were medium and glutathione-s-transferase (GST)
controls, NK1, NK2, NK3, and NK4. Polyacrylamide gel (7.5%) containing (A) 2% gelatin was used to observe the activities of MMP-2
and MMP-9, and (B) 2% casein to observe MMP-8 and MMP-9. Bands were quantified by Image J software for all MMPs, and closure of
bands gives the area exhibited in arbitrary units. Three independent experiments were carried out and statistical significance was
calculated (**p < 0.01 and ***p < 0.005) in comparison with the medium and GST controls.
536 R. Ramanujum et al.Quantification of cell proliferation is usually dealt with
by chromogen, and this is one of the most reliable methods
for assessing the viable cell number. Our results showed
that recombinant HGF variants started to show the inhibi-
tion of A549 cell proliferation in the Day 2 assay, and
continued on Days 4, 6, and 8, where they showed a slow
pace of growth compared to medium and GST controls
(Fig. 3). Our results are consistent with already published
data, where recombinant histidine-tagged HGF variants
inhibited the MDA-MB 435s cell line in a dose-dependent
manner [14].
Migration and invasion are important steps for cancer cell
metastasis, where many mutual interactions take place be-
tween linkers and adaptors, which degrade the ECM proteins
and decrease cell adhesion regulations. Our current resultsshow that inhibition of migration and invasion in A549 cells is
consistent with the proliferation assay. The pattern of inhi-
bition in the migration assay during 6 hours, 12 hours, 24
hours, and 36 hours was similar to the inhibition of prolifer-
ation in a 48-hour assay. NK4 was shown to be the strongest
inhibitor to migration, with over 50% of A549 cells being
delayed, and this was followed by NK2 (43%), NK1 (40%), and
NK3 (36%) (Fig. 4A), and all of these reached a significant
level in comparison to the medium and GST controls. In the
assays for A549 cell invasion, significant reduction (p< 0.05)
was shown in the presence of any of the HGF variants
(Fig. 4B). Although there is no evidence to show that prolif-
eration, migration, and invasion must be correlated, our
current results in lung cancer cells show that these three
processes are indeed significantly coordinated.
MMP expression regulated by HGF variants 537MMPs including MMP-9 and MMP-2 have been shown to
be overexpressed in a number of human pancreas cancer
cell lines; the activities of some MMPs can be inhibited by
miR-21 [47]. Some of the MMPs are involved in cancer
development by degrading and hence providing a meta-
static environment for cell translocation from one site to
another [48,49]. Even though HGF was shown to induce
some critical MMPs in various cancers, especially with
MMP-2 and MMP-9 in gastric and colon cancer [50,51],
there has been no report to date on the inhibition of
gelatinase B (MMP-9) by HGF variants. Therefore, our work
focuses on the study of the effects of human HGF variants
on the expression of MMP-2, MMP-9, and MMP-8. Our re-
sults showed that the expression of MMP-9 was reduced
(Fig. 5A) in the presence of any of the HGF variants. In the
same zymographic gels, however, MMP-2 expression in the
presence of any of the four NKs remained at similar level
to the controls, as reported in oral squamous cell carci-
noma [52]. By contrast, the inhibition of MMP-9 by NK1,
NK2, NK3, and NK4 was significant (p < 0.05; Fig. 5A).
Interestingly, we reported in our previous study that
overproduction of filamins stimulated by NK4 and NK3, but
not NK1 and NK2, happened via the STAT pathway [14].
Filamins are believed to stabilize the actin networks and
interact with numerous intracellular proteins, thus over-
production of the network protein stimulated by NK3 and
NK4 prolongs the cell cycle, stabilize the cancer cells, and
limit cell metastasis. Our current results reveal that the
downregulated expression of MMP-9 is another key inhib-
itory mechanism of HGF variants in proliferation, migra-
tion, and invasion of A549 cells.
We then went further to explore the expression of MMP-8
in A549 cells for the presence or absence of GST or each of
the HGF variants using casein zymography. Fortunately,
we found two extraordinarily expressed bands at 92 kDa
(MMP-9) and 75 kDa (MMP-8; Fig. 5B). The downregulated
expression of MMP-9 is similar to that in Fig. 5A, where it
was detected by gelatine zymography, but the expression
of MMP-8 in the two controls (A549 and A549 in the pres-
ence of GST) is so low that Image J software almost cannot
detect the presence in casein zymography. In the presence
of any of the four HGF variants, however, the expression
level of MMP-8 is significantly upregulated (Fig. 5B).
This appears to be the first report of overexpression of
MMP-8 stimulated by HGF variants detected by casein
zymography. MMP-8 might play a role in increasing cell
adhesion by rearrangement of cytoskeleton actin and thus
decreasing cell invasion [26]. Our current results suggest
that HGF variants might have been a specific signaling
effect for the production of MMP-8, which in turn increases
the adhesion capacity and reduces the metastatic potential
of A549 cells. Information to date shows that MMP-3 (stro-
melysin) activates MMP-9 [21] and procollagenases [34],
and MMP-7 (matrylysin) activates the MMP-8 in murine tis-
sue [53]. Furthermore, MMP-8 activity can be activated by
MT1-MMP in tears [54], and MT6-MMP activates MMP-2 and
MMP-9 [55]. It can be concluded that HGF variants stimulate
an upregulatory expression of MMP-8 and a downregulatory
expression of MMP-9 in the human lung cancer A549 cell,
and inhibit the proliferation, migration, and invasion of the
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